


SonoTran[®] Enhanced the Intra-tumoural Delivery of Systemically Administered Oncolytic Vaccinia Virus in a Human Liver Cancer (HepG2) Model

Vaccinia Virus + SonoTran[®]



SonoTran[®] enhanced the delivery of an oncolytic vaccinia virus by a factor of 50-fold in a murine model (measuring luminescence of the reporter gene expression and corroborated by qPCR) one day post IV injection. This 50-fold enhancement resulted in a 10,000-fold increase in vaccinia virus activity by day six.

Myers et al, Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus. *Molecular Therapy* (2016); 24 9, 1627-1633

Tumour volumes post treatment. Curves represent individual mice.

About OxSonics

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran[®] Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran[®] is being evaluated clinically and we're working with multiple partners to tackle the toughest cancers, head on.

Partner with us

By combining your therapeutic agent with SonoTran[®] we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.

By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.

Call:

+44 (0) 1865 784777

Email:

nicholas.adams@oxsonics.com

OxSonics Ltd

The Magdalen Centre
Oxford Science Park
Robert Robinson Avenue
Oxford, OX4 4GA
UK


www.oxsonics.com

SonoTran[®] Significantly Enhanced the Tumour Reduction of Oncolytic Vaccinia Virus in a Human Ovarian Cancer (SKOV) Model


Significantly enhanced tumour retardation in four out of four animals in the SonoTran[®]+ Vaccinia Virus group, compared to only one out of four animals in the Vaccinia Virus control group.

Myers et al, Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus. *Molecular Therapy* (2016); 24 9, 1627–1633

Vaccinia Virus



Vaccinia Virus + SonoTran[®]



Tumour volumes post treatment.
Curves represent individual mice.

About OxSonics

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran[®] Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran[®] is being evaluated clinically and we're working with multiple partners to tackle the toughest cancers, head on.

Partner with us

By combining your therapeutic agent with SonoTran[®] we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.

By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.

Call:

+44 (0) 1865 784777

Email:

nicholas.adams@oxsonics.com

OxSonics Ltd

The Magdalen Centre
Oxford Science Park
Robert Robinson Avenue
Oxford, OX4 4GA
UK

www.oxsonics.com